Stereoisomers of Schisandrin B Are Potent ATP Competitive GSK-3β Inhibitors with Neuroprotective Effects against Alzheimer’s Disease: Stereochemistry and Biological Activity
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Glycogen synthase kinase-3β (GSK-3β) is a key enzyme in hyperphosphorylation of tau proteins and is a promising therapeutic target in Alzheimer’s disease (AD). Here, we reported, for the first time, that the stereoisomers of Schisandrin B (Sch B), (+)- 1, (−)- 1, (+)- 2, and (−)- 2, were potent GSK-3β inhibitors. They were demonstrated to selectively target GSK-3β in an orthosteric binding mode, with IC 50 values of 340, 290, 80, and 70 nM, respectively. Further study showed that these stereoisomers can significantly increase the expression of p-GSK-3β (Ser9) and decrease the expressions of p-GSK-3β (Tyr216) and p-GSK-3β (Tyr279). Finally, these compounds can alleviate the cell injury induced by Aβ, and the cognitive disorders in AD mice, especially (+)- 2 and (−)- 2 . Collectively, the stereoisomers of Sch B, especially (+)- 2 and (−)- 2, were found to be potential selective ATP-competitive GSK-3β inhibitors, which further affected their anti-AD effects. These promising findings explained the biological target of Sch B in AD, and bring a new understanding in the stereochemistry and bioactivities of Sch B.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Administering these compounds has been shown to effectively mitigate memory deficits and markedly reduce the expression of phosphorylated tau in the hippocampus in the APP/PS1 double-transgenic mice.492”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [492]
In the citing paper
“Kadsuranin [(+)-2] (32) and gomisin N [( − )-2] (33), which are two stereoisomers of schisandrin B extracted from the fruits of S. chinensis, have been shown to effectively inhibit GSK-3β in an ATP-competitive manner.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [492]
Citations
Cites
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.017 · Cited by 744
Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain
PEI, J.-J., TANAKA, T., TUNG, Y.-C., BRAAK, E., IQBAL, K., & GRUNDKE-IQBAL, I. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199701000-00007 · Cited by 371
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
The Impact of Stereochemistry on Drug Development and Use
Aboul-Enein, H. Y., & Wainer, I. W. (1997) · Cited by 336
Szopa, A., Ekiert, R., & Ekiert, H. (2017) · Phytochemistry Reviews · doi:10.1007/s11101-016-9470-4 · Cited by 324
Bertrand, J. A., Thieffine, S., Vulpetti, A., Cristiani, C., Valsasina, B., Knapp, S., Kalisz, H. M., & Flocco, M. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.08.031 · Cited by 319
Developmental expression and localization of glycogen synthase kinase-3β in rat brain
Leroy, K., & Brion, J.-P. (1999) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(99)00012-5 · Cited by 238
Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease
Maqbool, M., Mobashir, M., & Hoda, N. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.10.018 · Cited by 227
Research works printed but not linked: 1
- Rester U., 2008, Curr. Opin. Drug Discovery Dev., 11, 559
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
A Comprehensive Review on Schisandrin B and Its Biological Properties
Nasser, M. I., Zhu, S., Chen, C., Zhao, M., Huang, H., & Zhu, P. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2172740 · Cited by 128
“Finally, in Alzheimer’s disease, Sch B was reported to reduce GSK-3β, a key enzyme necessary for the hyperphosphorylation of tan protein, therefore contributing to the protection of neurons from Alzheimer’s diseases [65].”
BackgroundYang, Y., Wang, L., Zhang, C., Guo, Y., Li, J., Wu, C., Jiao, J., & Zheng, H. Y. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14041 · Cited by 106
“There are three main phosphorylation sites of GSK- 3β, namely Tyr216, Ser9, and Ser389, among which Ser9 is the negative regulator of GSK- 3β (Hu et al., 2019).”
BackgroundYan, L., Guo, M.-S., Zhang, Y., Yu, L., Wu, J.-M., Tang, Y., Ai, W., Zhu, F.-D., Law, B. Y.-K., Chen, Q., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5288698 · Cited by 97
“It is reported that Schisandrin B increases the expression of p-GSK-3β (Ser9) but decreases the expressions of p-GSK-3β (Tyr216) and p-GSK-3β (Tyr279) and ultimately inhibits the activity of GSK-3β and the protein expression of Tau in APP/PS1 mice [292].”
GSK3: A potential target and pending issues for treatment of Alzheimer's disease
Zhao, J., Wei, M., Guo, M., Wang, M., Niu, H., Xu, T., & Zhou, Y. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14818 · Cited by 295
“265,266 Furthermore, several other natural products including paeoniflorin, 267 genistein, 231 berberine, 268 isobavachal-cone, 269 moscatilin, 270 xanthohumol, 271 resveratrol, 272 fisetin, 273 C-glycosylflavones, 274 geniposide, 275–277 ginkgolide A, 278 caffeic acid, 279 asiatic acid, 280…”
New insights into the role of GSK-3β in the brain: from neurodegenerative disease to tumorigenesis
Lai, S., Wang, P., Gong, J., & Zhang, S. (2023) · PeerJ · doi:10.7717/peerj.16635 · Cited by 68
Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects
Cheng, Z., Han, T., Yao, J., Wang, K., Dong, X., Fan, Y., Huang, H., Han, M., Liao, Q., He, S., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116065 · Cited by 62
Glycogen Synthase Kinase 3β Involvement in Neuroinflammation and Neurodegenerative Diseases
Gianferrara, T., Cescon, E., Grieco, I., Spalluto, G., & Federico, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220216113517 · Cited by 60
Progress in Target Drug Molecules for Alzheimer's Disease
Xie, J., Liang, R., Wang, Y., Huang, J., Cao, X., & Niu, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191203113745 · Cited by 60
Zhu, J., Wu, Y., Wang, M., Li, K., Xu, L., Chen, Y., Cai, Y., & Jin, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.566058 · Cited by 51
Wei, J., Wang, J., Zhang, J., Yang, J., Wang, G., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114301 · Cited by 42
Liu, X., Lai, L., Chen, J.-X., Li, X., Wang, N., Zhou, L., Jiang, X., Hu, X., Liu, W.-W., Jiao, X., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109525 · Cited by 33
Self-citationZhu, J., Wu, Y., Xu, L., & Jin, J. (2019) · Current Computer - Aided Drug Design · doi:10.2174/1573409915666190708102459 · Cited by 37
Zhao, Z., Yuan, Y., Li, S., Wang, X., & Yang, X. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14885 · Cited by 30
Epigenetic Studies of Chinese Herbal Medicine: Pleiotropic Role of DNA Methylation
Guo, W., Ma, H., Wang, C., Wan, J., Yao, H., & Yuan, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.790321 · Cited by 21
“It has been proved to have significant protective effects against Alzheimer’s disease (AD) (Hu et al., 2018).”
Backgroundde Sousa, N. F., Scotti, L., de Moura, É. P., Maia, M. D. S., Rodrigues, G. C. S., de Medeiros, H. I. R., Lopes, S. M., & Scotti, M. T. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211005145952 · Cited by 25
“Hu et al. [82] isolated four stereoisomers of Schisandrin B (Sch B) from the fruits of Schisandra chinensis and tested against the enzyme glycogen synthase kinase-3β (GSK-3β), which is a key enzyme in hyperphosphorylation of tau proteins and is a promising therapeutic target in AD.”
Schisandrin A and B enhance the dentate gyrus neurogenesis in mouse hippocampus
Cai, N., Wang, Z., Zhu, X.-C., Jiang, Y., Zhu, W., Yang, R., & Zhang, X. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101751 · Cited by 18
Self-citationWang, Q., Liu, L., Guan, H., Zhou, Y., & Li, Q. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.1941132 · Cited by 16
“For example, Sch A exerts a protective effect on AD rats by ameliorating cognitive impairments, endoplasmic reticulum stress, and neuroinflammation (Hu et al. 2019).”
BackgroundBACE1 inhibitors: A promising therapeutic approach for the management of Alzheimer’s disease
Arya, R., Jain, S., Paliwal, S., Madan, K., Sharma, S. K., Mishra, A., Tiwari, P. K., & Kadiri, S. K. (2024) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_192_24 · Cited by 20
Hosseini, A., Sheibani, M., & Valipour, M. (2024) · Phytotherapy Research · doi:10.1002/ptr.8329 · Cited by 14
Nieoczym, D., Banono, N. S., Stępnik, K. E., Kaczor, A. A., Szybkowski, P., Esguerra, C. V., Kukuła‐Koch, W., & Gaweł, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612949 · Cited by 11
“It has proven, among others, anti-inflammatory [34], antioxidant [22,35], cardioprotective [36], liver-protective [37], as well as neuroprotective [38,39] properties.”
BackgroundGlycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019–2024)
Joshi, S. V., Soujanya, D., Supriya, M. S., Yaddanapudi, V. M., & Nanduri, S. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2536003 · Cited by 10
“Out of the four stereoisomers of Sch B, 13 and 14 were found to be potent and selective ATP-competitive GSK-3β inhibitors, with IC 50 values of 0.08 and 0.07 µM, respectively [46].”
InfluentialRajamani, G., Naqvi, S. N. H., & Sharma, A. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00211g · Cited by 10
Wang, M., Huang, W., Huang, J., Shi, J., Huang, N., & Luo, Y. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100543 · Cited by 10
Chae, H., Kim, S. Y., Pel, P., Huh, J., Joo, S.-W., Lim, Y. Y., Park, S. J., Lim, J. L., & Chin, Y. (2020) · Molecules · doi:10.3390/molecules25133064 · Cited by 7
A review of developments in glycogen synthase kinase-3 regulators over the past 10 years
Wang, Y., Sun, K., Liu, J., Quan, Y., Lu, F.-Z., Quan, Z., Li, X., Shen, Q., & Luan, T. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117204 · Cited by 9
Schisandrin A and B affect the proliferation and differentiation of neural stem cells
Cai, N., Geng, Q., Jiang, Y., Zhu, W., Yang, R., Zhang, B., Xiao, Y., Tang, B., & Zhang, X. (2021) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2021.102058 · Cited by 6
Self-citationFeng, J., Li, L., Lv, X.-Y., Xiong, F., Hu, X., & Wang, H. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00417 · Cited by 5
Self-citationSchisandrin B Alleviates LPS Induced Mitochondrial Damage in C28I2 Cells
Hu, F., Hu, W., & Xu, H. (2024) · The Journal of Membrane Biology · doi:10.1007/s00232-023-00299-5 · Cited by 5
“Consequently, it can prevent or delay the onset of nerve damage (Hu et al. 2019; Qi et al. 2020).”
Chen, Y., Dong, H., 黄筱玲, Jiang, L., Jiang, Z., Li, L., Hu, J., & Chen, W.-H. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117639 · Cited by 4
Liu, X., Yu, J., Luo, Y.-Y., & Dong, H. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14111 · Cited by 6
“Therefore, GSK- 3β has become an important target of AD treatment (Hu et al., 2019; Tan et al., 2021; Wang et al., 2021).”
BackgroundChen, J., Zhang, L., Pu, Y., Chen, Y., Li, Y., Pan, X., & Chen, J. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230503094517 · Cited by 4
A Scaffold‐based Deep Generative Model Considering Molecular Stereochemical Information
Xu, T., Wang, M., Liu, X., Feng, D., Zhu, Y., Fan, Z., Rao, S., & Lu, J. (2022) · Molecular Informatics · doi:10.1002/minf.202200088 · Cited by 3
Boesger, H. A., Williams, K., Abdullai, S. A., Hubble, B., Noori, M. S., Orac, C. M., Amesaki, D., Ghazanfari, D., Fairchild, E. A., Fatunbi, O. O., et al. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.130074 · Cited by 2
Xu, Z., Zhou, M., Feng, Y., Han, Z., Li, Y., Yang, G., Wang, X., Zhang, K., & Liu, S. (2024) · Organic Letters · doi:10.1021/acs.orglett.4c02047 · Cited by 2
Zhao, X., Yin, J., Du, B., Fan, W., Chen, Y., Yang, Y., Fang, F., & Guan, J. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48010086
Su, C.-F., Deng, Z., Ying, K. Y., Liu, J., Guan, X., Kan, Y., Xu, X., Iyaswamy, A., Lu, K., Lu, J., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158795
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
Metadata
- Authors
- Hu, X.-L., Guo, C., Hou, J.-Q., Feng, J.-H., Zhang, X.-Q., Xiong, F., Ye, W.-C., & Wang, H.
- Affiliations
- State Key Laboratory of Natural Medicines, Department of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy. China Pharmaceutical University, Nanjing 210009, People’s Republic of China
- China Pharmaceutical University (CN)
- Jinan University (CN)
- State Key Laboratory of Digital Medical Engineering (CN)
- Corresponding author
- Wang, Hao
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-06-26
- Volume
- 10
- Issue
- 2
- Pages
- 996-1007
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2810868902
- Cited by
- 39
- References
- 40
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 9 · 2023: 5 · 2022: 7 · 2021: 4 · 2020: 4 · 2019: 2
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Government of Jiangsu Province (KYCX17_0694, KYLX15_0661)
- National Natural Science Foundation of China (81473160, 81573309)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Plant-derived Lignans Synthesis and Bioactivity
- Keywords
- schisandrin B, stereoisomers, GSK-3β inhibitors, ATP-competitive inhibition, Alzheimer's disease, neuroprotection, orthosteric binding, tau hyperphosphorylation, amyloid-beta toxicity, cognitive impairment
- MeSH terms
- Glycogen Synthase Kinase 3 beta, Adenosine Triphosphate, Alzheimer Disease, Animals, Cell Survival, Enzyme Inhibitors, Hippocampus, Humans, Male, Mice, Inbred ICR, Polycyclic Compounds, Stereoisomerism, Treatment Outcome, Lignans, Neuroprotective Agents, Cyclooctanes, Cell Line, Tumor, Mice, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.